Conditions: Rhinitis, Allergic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 704
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of mometasone furoate nasal spray (MFNS) with the addition of loratadine vs MFNS alone, loratadine alone, or placebo, in the treatment of patients with seasonal allergic rhinitis.

Detailed description:

Arms:
arm 1: Daily administration of 200 µg of MFNS plus oral dose of 10 mg loratadine tablet. arm 2: Daily administration of 200 µg of MFNS plus oral placebo tablet. arm 3: Daily administration of oral dose of 10 mg loratadine tablet plus placebo nasal spray. arm 4: Daily administration of placebo nasal spray plus oral placebo tablet.

Interventions: intervention 1: Mometasone furoate nasal spray (MFNS) intervention 2: Loratadine intervention 3: Placebo nasal spray intervention 4: Placebo tablet
Intervention descriptions: intervention 1: Daily dose of 200 µg of mometasone furoate administered as a nasal spray for 15 days. intervention 2: Daily dose of 10 mg of loratadine administered as an oral tablet for 15 days. intervention 3: Daily dose of placebo administered as a nasal spray for 15 days. intervention 4: Daily dose of placebo administered as an oral tablet for 15 days.

Protocol document: